基本信息
浏览量:629
职业迁徙
个人简介
His work focuses on the pharmacogenomics of GI cancers.
An active researcher, Dr. Lenz’s National Cancer Institute-funded laboratory is developing novel agents in his preclinical models in GI cancer. Lenz, a transformational clinical investigator and translational scientist, was the first to measure intratumoral RNA levels associated with efficacy of 5-FU and oxaliplatin and led the first prospective randomized Phase II trials using gene expression from FFPE specimens.
He also discovered that primary tumor location of colorectal cancer (CRC) is an independent predictive and prognostic marker, now in the NCNN guidelines. His paper on Consensus Molecular Subtyping identified novel subgroups that are predictive and prognostic in CRC, now used globally in drug development. He has been the Co-PI of the UG1 CA 062505 for the last 20 years and leads the NCCC site for the NCI UM1 (CA186717 with City of Hope, (UC Davis), and Stanford. He is Chair of the Translational Medicine Subcommittee in SWOG GI, member of the NCI Gastroesophageal Task Force and Clinical Trial Planning Committee, as well as the Investigational Drug Steering Committee. Lenz accelerates translational and clinical research and provides training and mentoring in the design and implementation of investigator-initiated trials. He was awarded a Career Development Award from STOP CANCER (1994-1997). Based on his research, he also received a Young Investigator Award from the American Society of Clinical Oncology (ASCO) in 1994. In 1995, Dr. Lenz was selected for the prestigious ASCO Career Development Award, as well as an NIH Mid-Career Development Award, in 1998. He has published over 450 peer reviewed manuscripts.
An active researcher, Dr. Lenz’s National Cancer Institute-funded laboratory is developing novel agents in his preclinical models in GI cancer. Lenz, a transformational clinical investigator and translational scientist, was the first to measure intratumoral RNA levels associated with efficacy of 5-FU and oxaliplatin and led the first prospective randomized Phase II trials using gene expression from FFPE specimens.
He also discovered that primary tumor location of colorectal cancer (CRC) is an independent predictive and prognostic marker, now in the NCNN guidelines. His paper on Consensus Molecular Subtyping identified novel subgroups that are predictive and prognostic in CRC, now used globally in drug development. He has been the Co-PI of the UG1 CA 062505 for the last 20 years and leads the NCCC site for the NCI UM1 (CA186717 with City of Hope, (UC Davis), and Stanford. He is Chair of the Translational Medicine Subcommittee in SWOG GI, member of the NCI Gastroesophageal Task Force and Clinical Trial Planning Committee, as well as the Investigational Drug Steering Committee. Lenz accelerates translational and clinical research and provides training and mentoring in the design and implementation of investigator-initiated trials. He was awarded a Career Development Award from STOP CANCER (1994-1997). Based on his research, he also received a Young Investigator Award from the American Society of Clinical Oncology (ASCO) in 1994. In 1995, Dr. Lenz was selected for the prestigious ASCO Career Development Award, as well as an NIH Mid-Career Development Award, in 1998. He has published over 450 peer reviewed manuscripts.
研究兴趣
论文共 1506 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
En Cheng,Fang-Shu Ou,Chao Ma,Alan P. Venook,Heinz-Josef Lenz, Eileen M. O’Reilly, Peter T. Campbell, Chaoyuan Kuang,Bette J. Caan,Kimmie Ng, Jeffrey A. Meyerhardt
Cancer Researchno. 6_Supplement (2024): 2200-2200
European journal of cancer (Oxford, England : 1990) (2024): 113914-113914
Cancer Causes & Controlno. 1 (2024): 111-120
Journal of clinical oncology : official journal of the American Society of Clinical Oncologypp.JCO2301507-JCO2301507, (2024)
Cancer Researchno. 6_Supplement (2024): 382-382
Heinz-Josef Lenz,Aparna Parikh,David R Spigel,Allen L Cohn,Takayuki Yoshino,Mark Kochenderfer,Elena Elez, Spencer H Shao, Dustin Deming,Regan Holdridge,Timothy Larson, Eric Chen,
Journal for immunotherapy of cancerno. 3 (2024)
Cancer research communicationsno. 1 (2024): 28-37
Jae Ho Lo,Shivani Soni,Goar Smbatyan, Lesly Torres-Gonzalez,Pooja Mittal,Yan Yang,Francesca Battaglin,Priscilla Chan,Yuanzhong Pan,Sandra Algaze,Priya Jayachandran, Karam Ashouri,
Cancer Researchno. 6_Supplement (2024): 7221-7221
Indrakant Kumar Singh,Shradheya RR Gupta,Pooja Mittal,Shivani Soni,Jae Ho Lo,Francesca Battaglin,Yan Yang, Lesly Torres-Gonzalez,Sandra Algaze,Priya Jayachandran,Karam Ashouri, Alexandra Wong,
Cancer Researchno. 6_Supplement (2024): 4495-4495
Akram Yazdani, Azam Yazdani,Raul Mendez-Giraldez, Gianluigi Pillonetto, Esmat Samiei, Reza Hadi,Heinz-Josef Lenz,Alan Venook,Ahmad Samiei,Andrew Nixon, Joseph Lucci rd,Scott Kopetz,
Research square (2024)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn